Alkermes announced positive results from the Vibrance-1 phase 2 study of Alixorexton in narcolepsy type 1 patients.
Alixorexton demonstrated significant improvements in wakefulness, cognition, and fatigue over a six-week period.
The drug was well tolerated at doses of 4 mg, 6 mg, and 8 mg.
Positive Results in Wakefulness and Cognition
Alixorexton showed significant improvements in wakefulness and cognitive function in patients with narcolepsy type 1.
Tolerability at All Doses
Patients tolerated Alixorexton well across all tested doses of 4 mg, 6 mg, and 8 mg.
Statistically Significant Efficacy
The drug demonstrated statistically significant improvements compared to placebo in key endpoints like mean sleep latency and Epworth Sleepiness Scale.
Reduction in Cataplexy
Alixorexton led to a reduction in cataplexy rates with over 40% of patients at higher doses achieving a 100% reduction during the study.
- The Vibrance-1 study showcased the potential of Alixorexton as a promising treatment option for narcolepsy type 1.
- Patients on Alixorexton experienced normalized wakefulness, reduced sleepiness, and improvements in cognitive function, indicating its broad impact on narcolepsy symptoms.
The detailed results of the Vibrance-1 study highlight the efficacy and tolerability of Alixorexton, positioning it as a potential new treatment for narcolepsy type 1.